RxDoctor Payments DataLook up a doctor →

Theodore Roosevelt, MD

Endocrinology, Diabetes & Metabolism · Boise, IDNPI 1699754697

Payments from drug & device makers

$64,550in general payments, 2019–2025

Across 566 payments — averaging $114.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$27K
  • Johnson & Johnson$13K
  • Novo Nordisk$9K
  • AbbVie$7K
  • Corcept Therapeutics$4K
  • Abbott$691
  • plus $4K from 26 others

What the payments were for

  • Consulting fees$9,94515%
  • Speaking & faculty fees$42,79566%
  • Travel & lodging$2,9835%
  • Food & beverage$8,80814%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,473
Medicare patients
114
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol130$175,211
OzempicSemaglutide90$128,645
Tresiba Flextouch U-200Insulin Degludec66$102,694
JardianceEmpagliflozin77$95,609
Tresiba Flextouch U-100Insulin Degludec87$57,171
Humalog Kwikpen U-200Insulin Lispro26$44,796
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog65$44,440
TrulicityDulaglutide41$43,260
CreonLipase/Protease/Amylase12$36,019
Repatha SyringeEvolocumab30$36,010
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$30,162
Xigduo XrDapaglifloz Propaned/Metformin31$29,571
JanuviaSitagliptin Phosphate18$27,091
Repatha SureclickEvolocumab41$25,543
KerendiaFinerenone14$23,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$26,640$175,211130 claims
Novo NordiskOzempic$9,421$128,64590 claims
Boehringer IngelheimJardiance, Synjardy Xr$299$107,73692 claims
Lilly USA, LLCTrulicity, Humalog$494$45,94454 claims
AbbVieCreon, Synthroid$6,916$45,407111 claims
MerckJanuvia$73$27,09118 claims
BayerKerendia$89$23,74614 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$337$15,09218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other endocrinology, diabetes & metabolism in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →